Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period

Vertex Pharmaceuticals Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period remained flat by 0.0% to 111.8K in Q4 2025 compared to the prior quarter.

Analysis

StatementIncome Statement

SectionOther

CategoryCapital Allocation

SignalContext dependent

VolatilityVolatile

First reportedQ1 2025

Last reportedQ4 2025Feb 13, 2026

How to read this metric

High exercise volume can indicate employee confidence in the stock or a desire to liquidate vested equity.

Detailed definition

The number of shares issued during the reporting period specifically due to the exercise of employee stock options. This...

Peer comparison

Standard disclosure in the statement of stockholders' equity for all public companies.

Metric ID: other_stock_issued_during_period_shares_stock_options_exercised

Historical Data

1 years

	FY'25
Value	447K

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period at Other Companies

General MotorsGM View metric

MSCIMSCI View metric

Corvex MOVE View metric

Vulcan Materials CompanyVMC View metric

Corvex MOVE View metric

PPG IndustriesPPG View metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, exercises in period?: Vertex Pharmaceuticals (VRTX) reported share-based compensation arrangement by share-based payment award, options, exercises in period of 111.8K in Q4 2025.
What does share-based compensation arrangement by share-based payment award, options, exercises in period mean?: The number of shares created when employees exercise their stock options.